文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

重症COVID-19患者早期使用托珠单抗与死亡率的关系

Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
PubMed 文献 · JAMA Intern Med · 2021-01-01
一句话结论多中心回顾性队列显示,重症COVID-19患者入住ICU前2天内使用托珠单抗与院内死亡风险降低相关(HR 0.71),但可能存在未测量混杂,需RCT验证。

该研究为多中心回顾性队列,纳入美国68家医院ICU的3924例重症COVID-19成人患者,比较入住ICU前2天内使用与未使用托珠单抗者的死亡风险。经逆概率加权调整混杂后,托珠单抗组死亡风险较低(HR 0.71;95%CI 0.56-0.92),30天死亡率27.5% vs 37.1%(风险差9.6%;95%CI 3.1%-16.0%)。作者指出该发现可能受未测量混杂影响,需随机对照试验进一步研究。

要点

  • 重症COVID-19成人入住ICU前2天内使用托珠单抗者,经逆概率加权后死亡风险低于未使用者(HR 0.71;95%CI 0.56-0.92)。
  • 托珠单抗组30天死亡率27.5%(95%CI 21.2%-33.8%),未使用组37.1%(95%CI 35.5%-38.7%),风险差9.6%(95%CI 3.1%-16.0%)。
  • 托珠单抗组患者更年轻(中位58岁 vs 63岁),且入ICU时低氧血症比例更高(机械通气且PaO2/FiO2<200 mmHg者47.3% vs 37.9%)。
  • 该研究为回顾性队列,作者明确提示 findings may be susceptible to unmeasured confounding,需RCT进一步验证。
  • 原文未提及托珠单抗的具体剂量、给药途径、频次或疗程。

适用人群与场景

  • 美国68家医院ICU收治的重症COVID-19成人患者,数据收集时间为2020年3月4日至5月10日,回顾性收集至2020年6月12日。
  • 纳入分析3924例(2464例男性,62.8%;中位年龄62岁,IQR 52-71)。
  • 按入住ICU前2天内是否使用托珠单抗分组:使用组433例(11.0%),未使用组3491例。

诊断标准与关键阈值

  • 原文未提及托珠单抗的启动阈值或停药标准。

处置流程与药物剂量

  • 原文未提及托珠单抗的具体剂量、给药途径、频次或疗程。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:多中心回顾性队列研究,68家医院,纳入3924例重症COVID-19成人患者。
  • 暴露:入住ICU前2天内使用托珠单抗 vs 未使用;主要终点为死亡时间(HR)和30天死亡率(风险差)。
  • 经逆概率加权Cox回归调整混杂后,托珠单抗组死亡风险低于未使用组(HR 0.71;95%CI 0.56-0.92)。
  • 30天死亡率:托珠单抗组27.5%(95%CI 21.2%-33.8%) vs 未使用组37.1%(95%CI 35.5%-38.7%),风险差9.6%(95%CI 3.1%-16.0%)。
  • 总死亡1544例(39.3%),其中托珠单抗组125例(28.9%),未使用组1419例(40.6%)。
  • 中位随访27天(IQR 14-37)。
  • 关键次要终点和不良事件:原文未提及。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 证据等级或推荐强度:原文未提及。
  • 局限:作者明确指出 findings may be susceptible to unmeasured confounding,且需要随机对照试验进一步研究。

对床旁实践的改变

  • 该回顾性队列提示,在重症COVID-19成人入住ICU前2天内使用托珠单抗者院内死亡风险较低(HR 0.71),但作者明确该发现可能受未测量混杂影响,需RCT验证;原文未给出剂量方案,不能据此形成具体用药推荐。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Therapies that improve survival in critically ill patients with coronavirus disease 2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 receptor, may counteract the inflammatory cytokine release syndrome in patients with severe COVID-19 illness.

OBJECTIVE: To test whether tocilizumab decreases mortality in this population.

DESIGN, SETTING, AND PARTICIPANTS: The data for this study were derived from a multicenter cohort study of 4485 adults with COVID-19 admitted to participating intensive care units (ICUs) at 68 hospitals across the US from March 4 to May 10, 2020. Critically ill adults with COVID-19 were categorized according to whether they received or did not receive tocilizumab in the first 2 days of admission to the ICU. Data were collected retrospectively until June 12, 2020. A Cox regression model with inverse probability weighting was used to adjust for confounding.

EXPOSURES: Treatment with tocilizumab in the first 2 days of ICU admission.

MAIN OUTCOMES AND MEASURES: Time to death, compared via hazard ratios (HRs), and 30-day mortality, compared via risk differences.

RESULTS: Among the 3924 patients included in the analysis (2464 male [62.8%]; median age, 62 [interquartile range {IQR}, 52-71] years), 433 (11.0%) received tocilizumab in the first 2 days of ICU admission. Patients treated with tocilizumab were younger (median age, 58 [IQR, 48-65] vs 63 [IQR, 52-72] years) and had a higher prevalence of hypoxemia on ICU admission (205 of 433 [47.3%] vs 1322 of 3491 [37.9%] with mechanical ventilation and a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen of <200 mm Hg) than patients not treated with tocilizumab. After applying inverse probability weighting, baseline and severity-of-illness characteristics were well balanced between groups. A total of 1544 patients (39.3%) died, including 125 (28.9%) treated with tocilizumab and 1419 (40.6%) not treated with tocilizumab. In the primary analysis, during a median follow-up of 27 (IQR, 14-37) days, patients treated with tocilizumab had a lower risk of death compared with those not treated with tocilizumab (HR, 0.71; 95% CI, 0.56-0.92). The estimated 30-day mortality was 27.5% (95% CI, 21.2%-33.8%) in the tocilizumab-treated patients and 37.1% (95% CI, 35.5%-38.7%) in the non-tocilizumab-treated patients (risk difference, 9.6%; 95% CI, 3.1%-16.0%).

CONCLUSIONS AND RELEVANCE: Among critically ill patients with COVID-19 in this cohort study, the risk of in-hospital mortality in this study was lower in patients treated with tocilizumab in the first 2 days of ICU admission compared with patients whose treatment did not include early use of tocilizumab. However, the findings may be susceptible to unmeasured confounding, and further research from randomized clinical trials is needed.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Gupta S, Wang W, Hayek SS, et al. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. JAMA Intern Med. 2021. PMID: 33080002. doi:10.1001/jamainternmed.2020.6252

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。